Literature DB >> 28115404

Concurrent pityriasis rosea and Bell's palsy.

Vanessa Voss1, Adam Mattox2, Mary Guo2.   

Abstract

Pityriasis rosea is a dermatological disease with a well-documented clinical appearance, but less is known about causes and treatment. Bell's palsy is a neurological condition leading to acute idiopathic hemifacial paralysis. Recent studies indicate that human herpesvirus (HHV) 6-7 reactivation may be a contributing factor to both conditions. We report a case of the 2 concurrent diagnoses that supports a common contributing factor and suggests further awareness and research into the role HHV 6-7 may play in the aetiology of both conditions. 2017 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28115404      PMCID: PMC5278325          DOI: 10.1136/bcr-2016-218069

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

Review 1.  Pityriasis rosea--an update.

Authors:  Antonio Chuh; Albert Lee; Vijay Zawar; Gabriel Sciallis; Werner Kempf
Journal:  Indian J Dermatol Venereol Leprol       Date:  2005 Sep-Oct       Impact factor: 2.545

2.  Temporal case clustering in pityriasis rosea: a regression analysis on 1379 patients in Minnesota, kuwait, and diyarbakir, Turkey.

Authors:  Antonio A T Chuh; Nicolas Molinari; Gabriel Sciallis; Mehmet Harman; Sedat Akdeniz; Arti Nanda
Journal:  Arch Dermatol       Date:  2005-06

3.  Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6.

Authors:  Takahiro Watanabe; Tatsuyoshi Kawamura; Sharon E Jacob; Elisabeth A Aquilino; Jan M Orenstein; Jodi B Black; Andrew Blauvelt
Journal:  J Invest Dermatol       Date:  2002-10       Impact factor: 8.551

4.  Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7.

Authors:  Francesco Broccolo; Francesco Drago; Anna M Careddu; Chiara Foglieni; Laura Turbino; Clementina E Cocuzza; Carlo Gelmetti; Paolo Lusso; Alfredo E Rebora; Mauro S Malnati
Journal:  J Invest Dermatol       Date:  2005-06       Impact factor: 8.551

5.  Pityriasis rosea and herpesviruses: facts and controversies.

Authors:  Alfredo Rebora; Francesco Drago; Francesco Broccolo
Journal:  Clin Dermatol       Date:  2010 Sep-Oct       Impact factor: 3.541

6.  Annualized incidence and spectrum of illness from an outbreak investigation of Bell's palsy.

Authors:  A M Morris; S L Deeks; M D Hill; G Midroni; W C Goldstein; T Mazzulli; R Davidson; S G Squires; T Marrie; A McGeer; D E Low
Journal:  Neuroepidemiology       Date:  2002 Sep-Oct       Impact factor: 3.282

Review 7.  Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology.

Authors:  Francesco Drago; Francesco Broccolo; Alfredo Rebora
Journal:  J Am Acad Dermatol       Date:  2009-08       Impact factor: 11.527

8.  Secretion and dynamics of herpes simplex virus in tears and saliva of patients with Bell's palsy.

Authors:  Yuzuru Abiko; Minoru Ikeda; Ryo Hondo
Journal:  Otol Neurotol       Date:  2002-09       Impact factor: 2.311

9.  Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  Gary S Gronseth; Remia Paduga
Journal:  Neurology       Date:  2012-11-07       Impact factor: 9.910

10.  Herpes simplex virus in the saliva of peripheral Bell's palsy patients.

Authors:  Paulo Roberto Lazarini; Melissa Ferreira Vianna; Mônica Porto Alves Alcantara; Rodolfo Alexander Scalia; Hélio Hehl Caiaffa Filho
Journal:  Braz J Otorhinolaryngol       Date:  2006 Jan-Feb
View more
  2 in total

Review 1.  The etiology of Bell's palsy: a review.

Authors:  Wenjuan Zhang; Lei Xu; Tingting Luo; Feng Wu; Bin Zhao; Xianqi Li
Journal:  J Neurol       Date:  2019-03-28       Impact factor: 4.849

2.  The use of antivirals in severe or recalcitrant cases of pityriasis rosea: A case series.

Authors:  Lihi Tzur; Fei-Shiuann Yang; Sandhya Deverapalli
Journal:  JAAD Case Rep       Date:  2022-06-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.